Literature DB >> 17525280

Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization.

Kanako Izumi-Nagai1, Norihiro Nagai, Yoko Ozawa, Masahiko Mihara, Yoshiyuki Ohsugi, Toshihide Kurihara, Takashi Koto, Shingo Satofuka, Makoto Inoue, Kazuo Tsubota, Hideyuki Okano, Yuichi Oike, Susumu Ishida.   

Abstract

Interleukin (IL)-6, a potent proinflammatory cytokine, is suggested to be a risk factor for choroidal neovascularization (CNV) because of its increased levels in the serum of patients with age-related macular degeneration; however, the role of IL-6 in CNV has not been defined. The present study reveals the critical contribution of IL-6 signaling and its downstream STAT3 pathway to the murine model of laser-induced CNV. CNV induction by laser treatment stimulated IL-6 expression in the retinal pigment epithelium-choroid complex, and antibody-based blockade of IL-6 receptor or genetic ablation of IL-6 led to significant suppression of CNV. CNV generation was accompanied by STAT3 activation in choroidal endothelial cells and macrophages, and IL-6 receptor blockade resulted in selectively inhibited phosphorylation of STAT3 but not extracellular signal-regulated kinase 1/2. Consistently, pharmacological blockade of STAT3 pathway also suppressed CNV. In addition, IL-6 receptor neutralization led to significant inhibition of the in vivo and in vitro expression of inflammation-related molecules including monocyte chemotactic protein, intercellular adhesion molecule-1, and vascular endothelial growth factor, and of macrophage infiltration into CNV. These results indicate the significant involvement of IL-6 receptor-mediated activation of STAT3 inflammatory pathway in CNV generation, suggesting the possibility of IL-6 receptor blockade as a therapeutic strategy to suppress CNV associated with age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525280      PMCID: PMC1899441          DOI: 10.2353/ajpath.2007.061018

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Characterization of anti-mouse interleukin-6 receptor antibody.

Authors:  Makoto Okazaki; Yoshiki Yamada; Norihiro Nishimoto; Kazuyuki Yoshizaki; Masahiko Mihara
Journal:  Immunol Lett       Date:  2002-12-03       Impact factor: 3.685

2.  The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Karen J Cruickshanks
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

3.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.

Authors:  Lin-Hung Wei; Min-Liang Kuo; Chi-An Chen; Chia-Hung Chou; Kuo-Bau Lai; Chien-Nan Lee; Chang-Yao Hsieh
Journal:  Oncogene       Date:  2003-03-13       Impact factor: 9.867

4.  JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.

Authors:  J De Vos; M Jourdan; K Tarte; C Jasmin; B Klein
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

5.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Authors:  Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2002-03

6.  The effect of chemical blockade of PKC with Gö6976 and Gö6983 on proliferation and MAPK activity in IL-6-dependent plasmacytoma cells.

Authors:  Ianko Iankov; Maria Praskova; Silvia Kalenderova; Zvetanka Tencheva; Ivan Mitov; Vanio Mitev
Journal:  Leuk Res       Date:  2002-04       Impact factor: 3.156

7.  Risk factors for age related maculopathy in a Japanese population: the Hisayama study.

Authors:  M Miyazaki; H Nakamura; M Kubo; Y Kiyohara; Y Oshima; T Ishibashi; Y Nose
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

8.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  N Takagi; M Mihara; Y Moriya; N Nishimoto; K Yoshizaki; T Kishimoto; Y Takeda; Y Ohsugi
Journal:  Arthritis Rheum       Date:  1998-12

9.  Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.

Authors:  Eiji Sakurai; Hogara Taguchi; Akshay Anand; Balamurali K Ambati; Evangelos S Gragoudas; Joan W Miller; Anthony P Adamis; Jayakrishna Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-06       Impact factor: 4.799

Review 10.  Joint disease caused by defective gp130-mediated STAT signaling.

Authors:  Tetsuji Naka; Tadamitsu Kishimoto
Journal:  Arthritis Res       Date:  2002-01-22
View more
  57 in total

1.  Control of chemokine gradients by the retinal pigment epithelium.

Authors:  Guangpu Shi; Arvydas Maminishkis; Tina Banzon; Stephen Jalickee; Rong Li; Jeffrey Hammer; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

Review 2.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

3.  Cholesterol crystals induce inflammatory cytokines expression in a human retinal pigment epithelium cell line by activating the NF-κB pathway.

Authors:  Yijun Hu; Haijiang Lin; Bernard Dib; Alp Atik; Peggy Bouzika; Christopher Lin; Yueran Yan; Shibo Tang; Joan W Miller; Demetrios G Vavvas
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

4.  Targeted deletion of Vegfa in adult mice induces vision loss.

Authors:  Toshihide Kurihara; Peter D Westenskow; Stephen Bravo; Edith Aguilar; Martin Friedlander
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

5.  Ocular cytomegalovirus latency exacerbates the development of choroidal neovascularization.

Authors:  Jinxian Xu; Xinglou Liu; Xinyan Zhang; Brendan Marshall; Zheng Dong; Yutao Liu; Diego G Espinosa-Heidmann; Ming Zhang
Journal:  J Pathol       Date:  2020-05-21       Impact factor: 7.996

6.  Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Authors:  Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

Review 7.  Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.

Authors:  Claudio Campa; Ciro Costagliola; Carlo Incorvaia; Carl Sheridan; Francesco Semeraro; Katia De Nadai; Adolfo Sebastiani; Francesco Parmeggiani
Journal:  Mediators Inflamm       Date:  2010-08-25       Impact factor: 4.711

8.  Regulation of the mucosal phenotype in dendritic cells by PPARγ: role of tissue microenvironment.

Authors:  Halide Tuna; Rita G Avdiushko; Vishal J Sindhava; Leia Wedlund; Charlotte S Kaetzel; Alan M Kaplan; Subbarao Bondada; Donald A Cohen
Journal:  J Leukoc Biol       Date:  2013-12-02       Impact factor: 4.962

Review 9.  Immunology of age-related macular degeneration.

Authors:  Jayakrishna Ambati; John P Atkinson; Bradley D Gelfand
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

10.  JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration.

Authors:  Hongjun Du; Xufang Sun; Monica Guma; Jing Luo; Hong Ouyang; Xiaohui Zhang; Jing Zeng; John Quach; Duy H Nguyen; Peter X Shaw; Michael Karin; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.